Rubius Therapeutics (RUBY) Announces 2020 Objectives and Provides Operational Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- L3Harris CEO steps down amid conduct review, shares drop
Rubius Therapeutics Announces 2020 Objectives and Provides Operational Update at the 38th Annual J.P. Morgan Healthcare Conference
January 13, 2020 8:01 AM ESTRTX-240 Investigational New Drug Application for Cancer on File with U.S. Food and Drug Administration
Rubius Manufacturing Facility Operational Nine Months Ahead of Schedule and
Ready to Supply Future Clinical Trials
Focus on Clinical Development to Advance Three Distinct Therapeutic Approaches Across
Rare Enzyme Deficiencies and Cancer
CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced 2020 objectives and... More
